CClinicalTrials.gg
Sign In
RecruitingNCT06542237Updated Feb 13, 2026

Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy Males

A Phase 1/2 interventional study of YCT-529 in Male Contraception, sponsored by YourChoice Therapeutics, Inc.. Recruiting at 1 site in New Zealand. Open to male participants aged 28 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by YourChoice Therapeutics, Inc. · Phase 1/2, Interventional, and Other

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years later.
Phase
Phase 1/2
Study type
Interventional
Enrollment
88
Allocation
Not applicable
Ages
28 Years to 70 Years
Sex
Male
01

Study summary

This is a Phase 1b/2a open-label, dose escalation 3 part-study, 28-day, 90-day or 180 day repeat dose study of YCT-529 in healthy males who have decided to have a vasectomy and are waiting for the procedure and for men who have decided not to father children in the future. The study is aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and to assess sexual function and mood.

Read the detailed description

This is a Phase 1b/2a, open label, 28-day, 90-day or 180-day repeat-dose escalation study of YCT-529 in healthy men to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics, and to assess sexual function and mood.

The study consists of 3 parts: a 28-day Phase 1b part (Part 1), a 90-day Phase 2a part (Part 2) and a 180-day Phase 2a part (Part 3). All participants will receive YCT-529.

In Part 1, 4 dosing cohorts and one optional 5th cohort with 4 participants each will be evaluated. In Part 2, up to 5 dosing cohorts and 2 optional cohorts with 4 participants each will be evaluated. Dose levels will be selected based on doses that were deemed safe and well tolerated upon 28-day administration in Part 1 and any previous Part 2 cohorts. Participants in Parts 1 and 2 may be replaced automatically if prior to any dosing. If a participant is required to be replaced post-dose, the replacement may beapproved at the discretion of Sponsor and PI with the objective of available data in at least 3 evaluable participants per cohort. In Part 3, 3 dosing cohorts and one optional 4th cohort with 10 participants each will receive doses within the range of doses that were deemed safe and well tolerated in Part 2. Participants who discontinue early may be replaced.

02

Conditions studied

  • Male Contraception

Keywords

  • male
  • non-hormonal
  • male contraception
  • healthy males
  • sperm count reduction
  • sperm motility
  • impaired spermatogenesis
  • impaired motility
  • orally administered
  • men
  • vasectomy
  • awaiting vasectomy
  • children
  • father
  • family planning
03

In context

Multiple Endocrine Neoplasia Type 1

50 studies on the registry are indexed under Multiple Endocrine Neoplasia Type 1; 18 are open to participants now.

This study's planned enrollment of 88 is above the median of 58 across 35 interventional studies indexed under Multiple Endocrine Neoplasia Type 1.

Browse Multiple Endocrine Neoplasia Type 1 studies →

Lead sponsor

YourChoice Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Participant in good health as confirmed by physical examination, medical history, and clinical laboratory tests.
  2. Participant must provide written informed consent.
  3. Participant must be willing and able to communicate and participate in the whole study.
  4. Participant is 28 to 70 years of age (inclusive) at the time of consent.
  5. Participant has decided to have a vasectomy and is waiting for the procedure or participant, in the opinion of the investigator, has made a firm decision not to father children in the future.
  6. Participant has a body mass index (BMI) 18.0 to 35.0 kg/m2.
  7. Participant has no history of hormonal therapy or 5-alpha reductase inhibitors use in the 90 days prior to the first screening visit.
  8. Participant with partner(s) of childbearing potential agrees to use a method of contraception that is highly effective with any partner (i.e., total abstinence or at a minimum, barrier method plus additional method of contraception) during the study until 28 days after the last dose (Day 56 [Part 1] or Day 118 [Parts 2 and 3]). Condom use is required during the course of the study with partner(s) of both childbearing and non-childbearing potential until Day 56 (Part 1) or Day 118 (Parts 2 and 3) to avoid potential secondary transmission of study drug and ensure the safety of the participants' sexual partner(s). Total abstinence from intercourse during the course of the study until Day 56 (Part 1) or Day 118 (Parts 2 and 3) is considered an acceptable form of contraception if this is in line with participant's preferred and/or usual lifestyle. Condom use is not required while practicing total abstinence.
  9. Participant will refrain from donating blood or plasma during the study.
  10. Participant will not use cannabis or any other recreational drugs for at least 30 days before the Screening visit and during the study. The marijuana/cannabis test can be positive at Screening but needs to be negative at admission (Day -1) for a volunteer to be eligible for inclusion in the study.
  11. Part 1: In the opinion of the investigator, participant is able to adhere to the study requirements, restrictions, schedule of assessments, and requirements related to sperm sample collection and maintenance of the sexual activity diary. Parts 2 and 3: In the opinion of the investigator, participant is able to adhere to the study requirements, restrictions, schedule of assessments, and requirements related to semen sample collection and maintenance of the electronic dosing diary.

  12. Part 1: Participant providing at least 2 semen samples during the screening period with sperm parameters within at least the 5th percentile of the WHO range of normality (WHO, 2010 and WHO, 2021):

    • 15 million sperm cells/mL
    • 39 million sperm cells/total ejaculate
    • 40% total motility
    • 30% progressive motility Parts 2 and 3: Participant providing 3 semen samples during the screening period with ≥ 15 million sperm cells/mL (at least the 5th percentile of the WHO range of normality [WHO, 2021]).

Exclusion criteria

Exclusion Criteria:

  1. Men participating in another clinical study involving an investigational drug within the last 30 days prior to the first dosing or less than 5 elimination half-lives prior to first dosing, whichever is longer.
  2. Clinically significant abnormal physical and/or laboratory findings at Screening
  3. Abnormal serum chemistry values at screening or admission, that indicate liver or kidney dysfunction or that may be considered clinically significant as determined by the PI, except for bilirubin >24 μmol/L and ALT, AST, GGT and ALP 2-fold above the upper limit of normal. Volunteers with known Gilbert's syndrome will be excluded if total bilirubin is ≥1.5 x ULN.
  4. Evidence of renal impairment at screening, as indicated by an estimated eGFR of \<80 mL/min/1.73 m2 using the 2021 CKD-EPI Creatinine Equation (https://www.kidney.org/professionals/kdoqi/gfr_calculator) .
  5. Use of androgens and selective androgen receptor modulators (SARMs) within 90 days before first screening visit.
  6. Volunteers with a body weight \< 55 kg.
  7. Systolic blood pressure (BP) >140 mmHg (\<45 years) or >160 mmHg (≥45 years) and diastolic BP >90 mmHg at screening and admission.
  8. Clinically significant abnormal electrocardiogram (ECG) or a duration of corrected QT interval using Bazett's and Fridericia's QT correction methods in ECG (QTc) interval of >450 msec at screening or predose.
  9. Known history of androgen deficiency due to hypothalamic-pituitary or testicular disease or multiple endocrine deficiencies.
  10. Known history of significant cardiovascular, renal, hepatic (cholecystectomy is not permitted), or prostatic disease. Gilbert's syndrome is allowed (volunteer with known Gilbert's syndrome will be excluded if total bilirubin is ≥1.5 x ULN). If volunteer has elevations only in total bilirubin that are >ULN and \<1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (i.e., direct bilirubin \<35% of the total bilirubin).
  11. Current or clinically relevant history of any psychiatric disorder or clinical assessment of significant suicidal risk or risk of self-injury as per the Investigator's judgement.
  12. Serious adverse reaction or serious hypersensitivity to any drug or formulation excipients.
  13. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Seasonal allergies (e.g., hay fever) are allowed unless considered clinically significant by the investigator.
  14. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) 1 and 2 antibody results at screening visit.
  15. Known or suspected alcoholism or drug abuse within the last 2 years that may affect metabolism/transformation of steroid hormones or study treatment compliance.
  16. Volunteers who do not have suitable veins for multiple venipunctures/cannulation as assessed by the investigator or delegate at screening.
  17. Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type.
  18. Current smokers who have consumed at least 5 cigarettes or equivalent amount of nicotine per week within the last 3 months prior to Screening.
  19. Confirmed positive drugs of abuse test result at Screening and admission and/or positive marijuana/cannabis test at admission (Day -1).
  20. Participants and volunteers who are taking, or have taken, any prescribed or over-the-counter drug or vitamins/herbal remedies/supplements (other than up to 4 g of paracetamol or up to 3.2 g of ibuprofen per day during the 14 days before IMP administration). COVID-19 vaccines are accepted concomitant medications. Other concomitant medications may be accepted at the discretion of both the PI and the Sponsor. Exceptions may apply, as determined by the investigator, if each of the following criteria are met: medication with a short half-life if the washout is such that no PD activity is expected by the time of dosing with IMP; and if the use of medication does not jeopardize the safety of the trial participant; and if the use of medication is not considered to interfere with the objectives of the study.
  21. Male volunteer with pregnant or lactating partner(s).
  22. Any site staff member with delegated study responsibilities or a family member of a site staff member with delegated study responsibilities.

  23. Any other medical condition that, in the opinion of the investigator, could alter the volunteer's well-being, the study conduct, or the interpretability of the results.

    -

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    YCT-529

    Open label, dose escalation, 3 part study (Phase 1b includes Part 1; Phase 2a includes Parts 2 and 3).

    Drug: YCT-529

Interventions

  • DrugYCT-529

    In Part 1, 4 dosing cohorts and one optional 5th cohort with 4 participants each will be evaluated. In Part 2, up to 5 dosing cohorts and 2 optional cohorts with 4 participants each will be evaluated. Dose levels will be selected based on doses that were deemed safe and well tolerated upon 28-day administration in Part 1 and any previous Part 2 cohorts. In Part 3, 3 dosing cohorts and one optional 4th cohort with 10 participants each will receive doses within the range of doses that were deemed safe and well tolerated in Part 2.

06

What researchers measure

Primary outcomes

  1. The incidence and nature of any adverse events, dose-limiting adverse events and serious adverse adverse events.

    Assessment of the number and type of adverse events, dose-limiting adverse events and serious adverse events following dosing.

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  2. Vital signs assessment (heart rate)

    Changes from pre-dose values (beats per minute)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  3. Vital signs assessment (blood pressure)

    Changes from pre-dose values (mm hg)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  4. Vital signs assessment (oral temperature)

    Changes from pre-dose values (temperature in celsius degrees)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  5. 12-lead ECG assessment (heart rate)

    Changes from pre-dose values (beats per minute)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  6. 12-lead ECG assessment (QT interval)

    Changes from pre-dose values for QT internal length (msec)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  7. 12-lead ECG assessment (QTcF Interval)

    Changes from pre-dose values for QTcF interval length (msec)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  8. 12-lead ECG assessment (PR Interval)

    Changes from pre-dose values for PR interval length (msec)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  9. 12-lead ECG assessment (QRS Duration)

    Changes from pre-dose values for QRS duration (msec)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  10. Clinical laboratory assessment- Hemoglobin Blood Sample Test

    Change from pre-dose value for hemoglobin (gm/dl)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  11. Clinical laboratory assessment- Hematocrit Blood Sample Test

    Change from pre-dose value for hematocrit (%)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  12. Clinical laboratory assessment- Packed Cell Volume Blood Sample Test

    Change from pre-dose value for packed cell volume (%)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  13. Clinical laboratory assessment- Red Blood Cell Sample Test

    Change from pre-dose value for red blood cells (g/dL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  14. Clinical laboratory assessment- Mean Corpuscular Volume Blood Sample Test

    Change from pre-dose value for mean corpuscular volume (fL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  15. Clinical laboratory assessment- Mean Corpuscular Hemoglobin Blood Sample Test

    Change from pre-dose value for mean corpuscular hemoglobin (MCH)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  16. Clinical laboratory assessment- Mean Corpuscular Hemoglobin Concentration Blood Sample Test

    Change from pre-dose value for mean corpuscular hemoglobin concentration (g/dL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  17. Clinical laboratory assessment- Platelet Count Blood Sample Test

    Change from pre-dose value for platelets (microL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  18. Clinical laboratory assessment- White Blood Cell Sample Test

    Change from pre-dose value for White blood cells (cells/L)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  19. Clinical laboratory assessment- Neutrophil Blood Sample Test

    Change from pre-dose value for Neutrophils (cells/L)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  20. Clinical laboratory assessment- Lymphocyte Blood Sample Test

    Change from pre-dose value for Lymphocytes (cells/mcL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  21. Clinical laboratory assessment- Monocyte Blood Sample Test

    Change from pre-dose value for Monocytes (cells/L)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  22. Clinical laboratory assessment- Eosinophil Blood Sample Test

    Change from pre-dose value for Eosinophils (%)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  23. Clinical laboratory assessment- Basophil Blood Sample Test

    Change from pre-dose value for Basophils (%)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  24. Clinical laboratory assessment- Coagulation Blood Sample Test

    Changes from pre-dose value for Prothrombin time (seconds)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  25. Clinical laboratory assessment- Activated Partial Thromboplastin Time Blood Sample Test

    Changes from pre-dose values for Activated partial thromboplastin time (seconds)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  26. Clinical laboratory assessment- Fibrinogen Blood Sample Test

    Changes from pre-dose value for Fibrinogen (mg/dL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  27. Clinical laboratory assessment -Sodium Blood Sample Tests

    Changes from pre-dose value for Sodium (mEq/L)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  28. Clinical laboratory assessment- Chloride Blood Sample Test

    Changes from pre-dose value for Chloride (mmol/L)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  29. Clinical laboratory assessment- Potassium Blood Sample Test

    Changes from pre-dose value for Potassium (mEq/L)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  30. Clinical laboratory assessment- Bicarbonate Blood Sample Test

    Changes from pre-dose value for Bicarbonate (mEq/L)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  31. Clinical laboratory assessment- Urea Blood Sample Test

    Changes from pre-dose value for Urea mmol/L

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  32. Clinical laboratory assessment -Creatinine Blood Sample Test

    Changes from pre-dose value for Creatinine (mg/dL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  33. Clinical laboratory assessment -Bilirubin (total) Blood Sample Test

    Changes from pre-dose value for Bilirubin (mg/dL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  34. Clinical laboratory assessment -Bilirubin (direct) Blood Sample Test

    Changes from pre-dose value for Bilirubin, direct only if total bilirubin is elevated (mg/dL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  35. Clinical laboratory assessment -Alkaline Phosphatase Blood Sample Test

    Changes from pre-dose value for Alkaline Phosphatase (U/L)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  36. Clinical laboratory assessment -Aspartate aminotransferase Blood Sample Test

    Changes from pre-dose value for Aspartate aminotransferase (U/L)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  37. Clinical laboratory assessment -Alanine aminotransferase Blood Sample Test

    Changes from pre-dose value for Alanine aminotransferase (U/L)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  38. Clinical laboratory assessment -Lactate dehydrogenase Blood Sample Test

    Changes from pre-dose value for Lactate dehydrogenase (U/L)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  39. Clinical laboratory assessment -Creatinine Kinase Blood Sample Test

    Changes from pre-dose value for Creatine kinase for (U/L)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  40. Clinical laboratory assessment - Gamma glutamyl transferase Blood Sample Test

    Changes from pre-dose value for Gamma glutamyl transferase (U/L)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  41. Clinical laboratory assessment - Troponin Blood Sample Test

    Changes from pre-dose value for Troponin (ng/mL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  42. Clinical laboratory assessment - Total Protein Blood Sample Test

    Changes from pre-dose value for Total Protein (g/dL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  43. Clinical laboratory assessment - Albumin Blood Sample Test

    Changes from pre-dose value for Albumin (g/dL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  44. Clinical laboratory assessment - Calcium Blood Sample Test

    Changes from pre-dose value for Calcium (mg/dL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  45. Clinical laboratory assessment - Fasting Glucose Blood Sample Test

    Changes from pre-dose value for Fasting Glucose (mg/dL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  46. Clinical laboratory assessment - Non Fasting Glucose Blood Sample Test

    Changes from pre-dose value for Non Fasting Glucose (mg/dL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  47. Clinical laboratory assessment - Fasting Triglycerides Blood Sample Test

    Changes from pre-dose value for Fasting Triglycerides (mg/dL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  48. Clinical laboratory assessment - Total Fasting Cholesterol Blood Sample Test

    Changes from pre-dose value for Total Fasting Cholesterol) (mg/dL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  49. Clinical laboratory assessment-Bilirubin Urine Sample Test

    Changes from pre-dose values for Bilirubin (mg/dL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  50. Clinical laboratory assessment-Urobilinogen Urine Sample Test

    Changes from pre-dose value for Urobilinogen (mmol/L)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  51. Clinical laboratory assessment- Ketones Urine Sample Test

    Changes from pre-dose value for Ketones (mmol/L)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  52. Clinical laboratory assessment- Glucose Urine Sample Test

    Changes from pre-dose value for Glucose (mmol/L)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  53. Clinical laboratory assessment- Protein Urine Sample Test

    Changes from pre-dose values for Protein (mg/dL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  54. Clinical laboratory assessment- Blood Urine Sample Test

    Changes from pre-dose value for Blood (RBC/HPF)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  55. Clinical laboratory assessment- Nitrites Urine Sample Test

    Changes from pre-dose value for Nitrites (mg/dL)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  56. Clinical laboratory assessment- pH Urine Sample Test

    Changes from pre-dose value for pH (pH value)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  57. Clinical laboratory assessment- Specific Gravity Urine Sample Test

    Changes from pre-dose value for Specific Gravity (USG)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  58. Clinical laboratory assessment- Leukocytes Urine Sample Test

    Changes from pre-dose value for Leukocytes (leukocytes per microscopic field)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

  59. Clinical laboratory assessment- High Sensitivity C- Reactive Protein

    Changes from pre-dose value for High Sensitivity C- Reactive Protein (mg/L)

    Time frame: For Part 1, from baseline to Day 280 and only in Part 2 from baseline to Day 360.

Secondary outcomes

  1. Plasma PK Parameter of YCT-529 (Area under the curve to Infinity [AUCinf])

    Plasma PK Parameter as measured by area under the curve from time 0 extrapolated to infinity \[AUCinf\]

    Time frame: Pre-dose to 28 days post last dose in Part 1, and from pre-dose to 30 days post last dose in Parts 2 and 3.

  2. Plasma PK Parameter of YCT-529 (Area under the curve to the last measured concentration [AUC0-t])

    Plasma PK Parameter as measured by area under the curve from time 0 to the last measured concentration \[AUC0-t\]

    Time frame: Pre-dose to 28 days post last dose in Part 1, and from pre-dose to 30 days post last dose in Parts 2 and 3.

  3. Plasma PK Parameter of YCT-529 (Area under the curve to 24 hours [AUC0-24])

    Plasma PK Parameter as measured by area under the curve from time 0 to 24 hours \[AUC0-24\]

    Time frame: Pre-dose to 28 days post last dose in Part 1, and from pre-dose to 30 days post last dose in Parts 2 and 3.

  4. Plasma PK Parameter of YCT-529 (Time to maximum concentration [Tmax])

    Plasma PK Parameter as measured by time to maximum concentration \[Tmax\]

    Time frame: Pre-dose to 28 days post last dose in Part 1, and from pre-dose to 30 days post last dose in Parts 2 and 3.

  5. Plasma PK Parameter of YCT-529 (Terminal elimination half life [T1/2])

    Plasma PK Parameter as measured by terminal elimination half life \[T1/2\]

    Time frame: Pre-dose to 28 days post last dose in Part 1, and from pre-dose to 30 days post last dose in Parts 2 and 3.

  6. Plasma PK Parameter of YCT-529 (Lag time [Tlag])

    Plasma PK Parameter as measured by lag time \[Tlag\]

    Time frame: Pre-dose to 28 days post last dose in Part 1, and from pre-dose to 30 days post last dose in Parts 2 and 3.

  7. Plasma PK Parameter of YCT-529 (Volume of distribution [Vz/F])

    Plasma PK Parameter as measured by apparent volume of distribution \[Vz/F\]

    Time frame: Pre-dose to 28 days post last dose in Part 1, and from pre-dose to 30 days post last dose in Parts 2 and 3.

  8. Plasma PK Parameter of YCT-529 (oral clearance [CL/F])

    Plasma PK Parameter as measured by oral clearance \[CL/F\] of YCT-529

    Time frame: Pre-dose to 28 days post last dose in Part 1, and from pre-dose to 30 days post last dose in Parts 2 and 3.

  9. Plasma PK Parameter of YCT-529 (maximum concentration [Cmax])

    Plasma PK Parameter as measured by maximum concentration \[Cmax\]) of YCT-529

    Time frame: Pre-dose to 28 days post last dose in Part 1, and from pre-dose to 30 days post last dose in Parts 2 and 3.

  10. Pharmacodynamic parameter of YCT-529, including follicle-stimulating hormone

    Changes from pre-dose values of follicle-stimulating hormone

    Time frame: Pre-dose to 28 days post last dose in Part 1, and from pre-dose to 30 days post last dose in Parts 2 and 3.

  11. Pharmacodynamic parameter of YCT-529, including luteinizing hormone

    Changes from pre-dose values of luteinizing hormone

    Time frame: Pre-dose to 28 days post last dose in Part 1, and from pre-dose to 30 days post last dose in Parts 2 and 3.

  12. Pharmacodynamic parameter of YCT-529, including estradiol

    Changes from pre-dose values of luteinizing hormone

    Time frame: Pre-dose to 28 days post last dose in Part 1, and from pre-dose to 30 days post last dose in Parts 2 and 3.

  13. Pharmacodynamic parameter of YCT-529, including testosterone

    Changes from pre-dose values of testosterone

    Time frame: Pre-dose to 28 days post last dose in Part 1, and from pre-dose to 30 days post last dose in Parts 2 and 3.

  14. Changes in YCT-529 concentrations in semen

    Changes in YCT-529 as measured by changes in serum concentrations in semen

    Time frame: Pre-dose to 28 days post last dose in Part 1, and from pre-dose to 30 days post last dose in Parts 2 and 3.

07

Study locations

1 of 1 sites recruiting
  • New Zealand Clinical Research (NZCR)
    Grafton, Auckland 1010, New Zealand
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06542237
Lead sponsor
YourChoice Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 7, 2024
Start date
Sep 11, 2024
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Feb 13, 2026

Study contacts

Nadja Mannowetz, PhD
Contact
ClinicalTrial@ychoicetx.com
415-233-6970
Rohit Katia, MBChB
principal investigator · New Zealand Clinical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Multiple Endocrine Neoplasia Type 1→

Other studies from this sponsor

YourChoice Therapeutics, Inc.

Start the discussion